Key takeaways

The Federal Trade Commission secured a landmark settlement with Express Scripts and its parent company, Cigna.

The agreement resolves antitrust allegations concerning the pharmacy benefit manager's insulin pricing practices.

Express Scripts must adopt fundamental changes to its business practices and overhaul its drug pricing models.

The stated goal of the federal regulatory action is to help lower drug costs for American patients.

The Decision

The Federal Trade Commission announced on February 4, 2026 that it reached a landmark settlement with pharmacy benefit manager Express Scripts, Inc., its affiliated entities, and its parent company, Cigna. The agreement resolves federal antitrust allegations targeting the company's insulin pricing practices. To resolve the inquiry, Express Scripts agreed to adopt fundamental changes to its business practices and overhaul the drug pricing models it uses to negotiate with pharmaceutical manufacturers and retail pharmacies. The federal regulatory action represents a direct challenge to the intermediary structures that govern medication access in the United States.

Why It Matters

Pharmacy benefit managers act as powerful intermediaries between drug manufacturers, insurance providers, and pharmacies. When a federal regulator forces one of the largest entities in this sector to alter its core business model, the action signals a definitive shift in antitrust enforcement priorities. By requiring an overhaul of drug pricing models, the settlement attacks the structural mechanisms that determine consumer out-of-pocket expenses for essential therapies.

Legal practitioners can read this as a clear indicator that federal regulators view traditional pharmacy benefit manager rebate and pricing structures as vulnerable to antitrust scrutiny. Historically, antitrust enforcement in the pharmaceutical sector concentrated on the manufacturers themselves, targeting issues like patent thickets or pay-for-delay settlements. Turning the enforcement lens toward the middlemen requires a different theory of competitive harm. The focus on insulin pricing practices suggests the Federal Trade Commission is willing to use its authority to address markets where intermediaries allegedly distort pricing signals, resulting in higher costs for end users. The mandated overhaul indicates that regulators demand structural, operational reform rather than relying solely on financial penalties.

Who Should Care

For lawyers

Antitrust attorneys, compliance officers, and corporate counsel advising healthcare intermediaries must evaluate their clients' pricing models against the terms of this settlement. Because the agreement requires fundamental changes to business practices, counsel should anticipate heightened regulatory demands during investigations into rebate negotiations, formulary placements, and pharmacy reimbursement rates. Lawyers representing competing pharmacy benefit managers should prepare for the possibility that the Federal Trade Commission will use the Express Scripts agreement as a template for future enforcement actions. Firms advising pharmaceutical manufacturers also need to monitor how this overhaul affects their clients' negotiation strategies with pharmacy benefit managers.

For consumers and patients

American patients who rely on insulin face famously high out-of-pocket costs. The stated goal of the settlement is to help lower drug costs for American patients. By forcing a major pharmacy benefit manager to change how it prices medications, consumers may see adjustments in how their health plans cover essential therapies at the pharmacy counter. While the settlement focuses specifically on insulin, the required overhaul of drug pricing models could eventually influence how other chronic disease medications are priced and covered.

Legal Background

Federal antitrust enforcement in the pharmaceutical sector historically focused on patent settlements and hospital mergers. Pharmacy benefit managers operated largely outside direct federal price-setting intervention, relying on complex rebate negotiations with manufacturers to determine which drugs appear on insurance formularies. Under general antitrust principles, regulators examine whether business practices unreasonably restrain trade or constitute unfair methods of competition.

For years, the intermediary nature of pharmacy benefit managers made it difficult for regulators to pinpoint competitive harm. The middlemen argued that their bulk purchasing power actually reduced costs for health plans. However, as out-of-pocket costs for medications like insulin continued to rise, federal scrutiny intensified. The FTC Secures Landmark Settlement with Express Scripts to Lower Drug Costs for American Patients announcement represents a departure from earlier, narrower enforcement actions. Regulators are now directly challenging the pricing practices of intermediaries rather than focusing solely on drug manufacturers, signaling a broader interpretation of what constitutes anticompetitive behavior in healthcare markets.

What the Commission Did

In pursuing Ftc v. Express Scripts, the Federal Trade Commission targeted the specific mechanisms the pharmacy benefit manager used to price insulin. Rather than merely imposing a financial penalty, the agency required Cigna and Express Scripts to commit to an overhaul of their drug pricing models.

The commission determined that fundamental changes to the company's business practices were necessary to address the allegations regarding insulin pricing. By securing commitments to overhaul these models, the federal government is effectively dictating the terms under which a major healthcare intermediary can operate. The settlement forces the company to abandon or modify the specific pricing practices that the agency alleged were driving up the cost of insulin. This structural remedy aims to correct the market dynamics at the source.

How It May Be Applied

This settlement provides a framework for future federal actions against other pharmacy benefit managers. Regulators may use the commitments extracted from Express Scripts as a baseline for industry-wide compliance. If the mandated overhaul of drug pricing models successfully lowers costs for American patients, the Federal Trade Commission will likely apply similar pressure to competing healthcare intermediaries facing scrutiny over their handling of specialty medications and chronic disease treatments.

Furthermore, state attorneys general and private plaintiffs often follow the federal government's lead in antitrust matters. The allegations regarding insulin pricing practices could spawn parallel state-level investigations or civil litigation targeting similar intermediary behavior. Healthcare counsel must watch closely to see exactly how Express Scripts implements these fundamental changes to its business practices, as those operational shifts will define the new regulatory safe harbors for the entire pharmacy benefit management industry.

Comparing Traditional Intermediary Operations and the Settlement Terms

Operational Aspect	Traditional Industry Practice	Settlement Mandate
Pricing Models	Complex, opaque rebate negotiations	Mandated overhaul of drug pricing models
Regulatory Enforcement	Focus on manufacturers; limited intermediary scrutiny	Direct intervention; fundamental changes to business practices required
Consumer Impact	High out-of-pocket insulin expenses	Stated goal to help lower drug costs for American patients
Remedy Structure	Occasional financial penalties	Structural and operational reform commitments

The Bottom Line

In simple terms, the federal government forced a major corporate middleman to change how it prices a life-saving drug. Pharmacy benefit managers like Express Scripts negotiate the prices your insurance pays for medications. The Federal Trade Commission accused the company of using practices that kept insulin prices artificially high. To settle the case, Express Scripts and its parent company, Cigna, agreed to rewrite their pricing rules. The agency demanded these operational changes with the specific aim of making insulin cheaper for the people who need it. This agreement shows that federal regulators are expanding their focus beyond drug manufacturers to actively police the middlemen who decide how much medications cost at the pharmacy counter.

This article is general legal information and commentary about legal developments. It is not legal advice, does not address your specific situation, and is not a substitute for advice from a licensed attorney. Reading this article and contacting us through this website do not create an attorney-client relationship.

Sources & authorities

FTC Secures Landmark Settlement with Express Scripts to Lower Drug Costs for American Patients — source
Ftc v. Express Scripts — source

FTC Settles Express Scripts Insulin Pricing Case to Lower Costs

Key takeaways